Matrix metalloproteinases: Potential therapeutic target in spinal cord injury

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 4, 2001, Pages 362-367

  Duchossoy, Yann ^a   Arnaud, Sonia ^a   Feldblum, Sophie ^a  

^a Neurolab   (France)

Author keywords

Gelatinase; Metalloproteinases; Spinal injury; Zymography: in situ

Indexed keywords

ANTIBODY; GELATINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL LEVEL; CONTROLLED STUDY; CONTUSION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXTRACELLULAR MATRIX; FEMALE; FLUORESCENCE; FROZEN SECTION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD INJURY; VASCULARIZATION; ZYMOGRAPHY;

ANIMALS; CONTUSIONS; EXTRACELLULAR MATRIX; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KINETICS; LEUKOCYTES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; SPINAL CORD INJURIES; TIME FACTORS;

ANIMALIA;

EID: 0035036509     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.057     Document Type: Article

References (43)

1. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998; 21:75-80.
2. Murphy G, Reynolds J. Extracellular matrix degradation. In: Royce P, Steinmann B, editors. Connective tissue and its heritable disorders. New York: Wiley-Liss, 1993;287-316.
3. Ward RV, Hembry RM, Reynolds JJ, Murphy G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. Biochem J 1991; 278:179-87.
4. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, et al. Antisens RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989; 243:947-50.
5. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994; 81:69-77.
6. Mohanam S, Wang SW, Rayford A, Yamamoto M, Sawaya R, Nakajima M, et al. Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 1995; 13:57-62.
7. Dayer JM, Burger D. Interleukine-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw 1994; 5:563-71.
8. Hodgson J. Remodeling MMPIs. Biotechnology 1995; 13:554-7.
9. Anthony DC, Miller KM, Fearn S, Townsend MJ, Opdenakker G, Wells GMA, et al. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998; 87:62-72.
10. Chong YH, Seoh JY, Park HK. Increased activity of metalloproteinase-2 in human glial and neuronal cell lines treated with HIV-1 gp41 peptides. J Mol Neurosci 1998; 10:129-41.
11. Giannelli G, Kalk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by MMP-2 cleavage of laminin-5. Science 1997; 277:225-8.
12. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinases degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinases (PUMP). Biochem J 1991; 277:277-9.
13. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic-protein. Neurosci Lett 1995; 201:223-6.
14. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29:1020-30.
15. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. Tumor necrosis factor-alpha-induced gelatinase B caused delayed opening of the blood-brain barrier: an expanded therapeuthic window. Brain Res 1995; 703:151-5.
16. Donovan FM, Hegstrom CD, Noble LJ, Werb Z. Matrix metalloproteinases in spinal cord injury [abstract]. Neurosci Abstr 2000; 186.4.
17. Feldblum S, Arnaud S, Simon M, Rabin O, d'Arbigny P. Efficacy of a new neuroprotective agent, Gacyclidine, in a model of rat spinal cord injury. J Neurotrauma 2000; 17:1073-89.
18. Oh LYS, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, et al. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 1999; 19:8464-75.
19. Martin D, Schoenen J, Delree P, Gilson V, Rogister B, Leprince P, et al. Experimental acute traumatic injury of the adult rat spinal cord by a subdural inflatable balloon: methodology, behavioral analysis, and histopathology. J Neurosci Res 1992; 32:539-50.
20. Dusart I, Schwab ME. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci 1994; 6:712-24.
21. Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L. Acute inflammatory response in spinal cord following impact injury. Exp Neurol 1998; 151:77-88.
22. Lou J, Gasche Y, Zheng L, Giroud C, Morel P, Clements J, et al. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest 1999; 79:1015-25.
23. Harkness KA, Adamson P, Sussman D, Davies-Jones GA, Greenwood J, Woodroofe MN. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000; 123:698-709.
24. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576:203-7.
25. De Castro R, Burns C, McAdoo D, Romanic A. Metalloproteinase increases in the injured rat spinal cord. Neuroreport 2000, 16:4959-65.
26. Hiraoka N, Allen E, Apel I, Gyetko M, Weiss S. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998, 95:365-77.
27. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48:3307-12.
28. Reith A, Rucklidge GJ. Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Commun 1992; 186:348-54.
29. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-4.
30. Zhu WH, Guo X, Villaschi S, Francesco Nicosia R. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab Invest 2000; 80:545-55.
31. De Lorenzo MS, Alonso DF, Gomez DE. Nafoxidine modulates the expression of matrix-metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in endothelial cells. Anticancer Res 2000; 20:395-400.
32. Iwasaka C, Tanaka K, Abe M, Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J cell Physiol 1996; 169:522-31.
33. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49:117-37.
34. Zucker S, Conner C, Di Massno BI, Ende H, Drews M, Seiki M, Bahou WF. Thrombin induces the activation of progelatinase A in vascular endothelial cells: physiologic regulation of angiogenesis. J Biol Chem 1995; 270:23730-8.
35. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in case of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23:406-15.
36. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79:319-26.
37. Schlosshauer B. The blood-brain barrier: morphology, molecules and neurothelin. Bioessays 1993; 15:341-6.
38. Hirschberg DL, Yoles E, Belkin M, Schwartz M. Inflammation after axonal injury has conflicting consequences for recovery of function: rescue of spared axons is impaired but regeneration is supported. J Neuroimmunol 1994; 50:9-16.
39. Blight AR. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma 1985; 2: 299-315.
40. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukocyte Biol 1995; 57:774-7.
41. Zhang Z, Guth L. Experimental spinal cord injury: wallerian degeneration in the dorsal column is followed by revascularization, glial proliferation, and nerve regeneration. Exp Neurol 1997; 147:159-71.
42. Hiraizumi YEE, Transfeldt N, Kawahara VD, Fiegel D, Knighton D, Sung JH. The effect of growth factor formula (platelet derived wound healing formula) in experimental spinal cord injuries. J Am Paraplegia Soc 1992; 15:7-13.
43. Davis S, Bouchard C, Tsatas O, Giftochristos N. Macrophages can modify the nonpermissive nature of the adult mammalian central nervous system. Neuron 1990; 5:463-9.